Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF)

Toshiyuki Nagai, Yasuyuki Honda, Hiroki Nakano, Satoshi Honda, Naotsugu Iwakami, Atsushi Mizuno, Nobuyuki Komiyama, Takafumi Yamane, Yutaka Furukawa, Tadayoshi Miyagi, Syuzo Nishihara, Nobuhiro Tanaka, Taichi Adachi, Toshimitsu Hamasaki, Yasuhide Asaumi, Yoshio Tahara, Takeshi Aiba, Yasuo Sugano, Hideaki Kanzaki, Teruo NoguchiKengo Kusano, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Backgrounds: Despite current therapies, acute heart failure (AHF) remains a major public health burden with high rates of in-hospital and post-discharge morbidity and mortality. Carperitide is a recombinantly produced intravenous formulation of human atrial natriuretic peptide that promotes vasodilation with increased salt and water excretion, which leads to reduction of cardiac filling pressures. A previous open-label randomized controlled study showed that carperitide improved long-term cardiovascular mortality and heart failure (HF) hospitalization for patients with AHF, when adding to standard therapy. However, the study was underpowered to detect a difference in mortality because of the small sample size. Methods: Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF) is a multicenter, randomized, open-label, controlled study designed to evaluate the efficacy of intravenous carperitide in hospitalized patients with AHF. Patients hospitalized for AHF will be randomly assigned to receive either intravenous carperitide (0.02 μg/kg/min) in addition to standard treatment or matching standard treatment for 72 h. The primary end point is death or rehospitalization for HF within 2 years. A total of 260 patients will be enrolled between 2013 and 2018. Conclusion: The design of LASCAR-AHF will provide data of whether carperitide reduces the risk of mortality and rehospitalization for HF in selected patients with AHF.

Original languageEnglish
Pages (from-to)551-557
Number of pages7
JournalCardiovascular Drugs and Therapy
Issue number5-6
Publication statusPublished - 2017 Dec 1


  • Acute heart failure
  • Carperitide
  • Death
  • Rehospitalization


Dive into the research topics of 'Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF)'. Together they form a unique fingerprint.

Cite this